Faculty Opinions recommendation of 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.

2012 ◽  
Author(s):  
Hendrik van Poppel ◽  
Yuri Tolkach
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Neoadjuvant Treatment ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
Receptor Inhibitor

Novelties of treatment in advanced renal-cell cancer

2011 ◽  
Vol 152 (17) ◽  
pp. 655-662 ◽  
Author(s):  
Anikó Maráz
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Tyrosine Kinase ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Current Evidence ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
Advanced Renal Cell Cancer

Therapeutic options in advanced renal-cell cancer have expanded through better understanding of molecular patho­logy and development of novel targeted therapeutics. Vascular endothelial growth factor, the key ligand of angioge­nesis, has a major role in the progression of vascularized kidney tumors and this is the target molecule of modern medications. The three types of the mechanism of action of current therapies are: monoclonal antibodies blocking directly vascular endothelial growth factor ligand (bevacizumab), tyrosine-kinase inhibitors blocking vascular endothelial growth factor receptors (sorafenib, sunitinib, pazopanib) and inhibitors of the intracellular mTOR-kinase (temsirolimus, everolimus). Based on randomized studies, sunitinib, pazopanib or interferon-α-bevacizumab combination should be the first-line therapy in patients with good/moderate prognosis, while temsirolimus is recommended in those with poor prognosis. Following an ineffective cytokine therapy sorafenib or pazopanib are the se­cond-line treatment. In case of tyrosine-kinase inhibitor inefficacy, current evidence favors everolimus. Patient outcome can further be improved by the involvement of more modern and effective target products. Orv. Hetil., 2011, 152, 655–662.

Sign in / Sign up

Export Citation Format

Share Document